| Bioactivity | SYHA1815 is an orally active RET inhibitor (IC50=0.9 nmol/L) with antitumor activity. SYHA1815 is more selective for RET than KDR (IC50=15.9 nmol/L). SYHA1815 arrests the G1 cell cycle and inhibits RET-driven cell proliferation by downregulating c-Myc[1]. |
| CAS | 2760195-67-1 |
| Formula | C27H26ClF4N5O |
| Molar Mass | 547.97 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yuchen Jiang, et al. "The novel RET inhibitor SYHA1815 inhibits RET-driven cancers and overcomes gatekeeper mutations by inducing G1 cell-cycle arrest through c-myc downregulation." Molecular Cancer Therapeutics 20.11 (2021): 2198-2206. |
SYHA1815
CAS: 2760195-67-1 F: C27H26ClF4N5O W: 547.97
SYHA1815 is an orally active RET inhibitor (IC50=0.9 nmol/L) with antitumor activity. SYHA1815 is more selective for RET
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.